HRP20171188T1 - Hidrokloridne soli antibiotskog spoja - Google Patents

Hidrokloridne soli antibiotskog spoja

Info

Publication number
HRP20171188T1
HRP20171188T1 HRP20171188TT HRP20171188T HRP20171188T1 HR P20171188 T1 HRP20171188 T1 HR P20171188T1 HR P20171188T T HRP20171188T T HR P20171188TT HR P20171188 T HRP20171188 T HR P20171188T HR P20171188 T1 HRP20171188 T1 HR P20171188T1
Authority
HR
Croatia
Prior art keywords
hydrochloride salts
antibiotic compound
antibiotic
compound
hydrochloride
Prior art date
Application number
HRP20171188TT
Other languages
English (en)
Croatian (hr)
Inventor
Weijiang Zhang
Ronnie Cheung
Dimitar Filipov
Jack Green
Junning Lee
Original Assignee
Theravance Biopharma Antibiotics Ip, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma Antibiotics Ip, Llc filed Critical Theravance Biopharma Antibiotics Ip, Llc
Publication of HRP20171188T1 publication Critical patent/HRP20171188T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K9/00Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HRP20171188TT 2013-03-13 2014-03-06 Hidrokloridne soli antibiotskog spoja HRP20171188T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361779065P 2013-03-13 2013-03-13
EP14717248.0A EP2968446B1 (en) 2013-03-13 2014-03-06 Hydrochloride salts of an antibiotic compound
PCT/US2014/021064 WO2014158952A1 (en) 2013-03-13 2014-03-06 Hydrochloride salts of an antibiotic compound

Publications (1)

Publication Number Publication Date
HRP20171188T1 true HRP20171188T1 (hr) 2017-10-06

Family

ID=50483481

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20171188TT HRP20171188T1 (hr) 2013-03-13 2014-03-06 Hidrokloridne soli antibiotskog spoja

Country Status (32)

Country Link
US (1) US9161990B2 (cg-RX-API-DMAC7.html)
EP (1) EP2968446B1 (cg-RX-API-DMAC7.html)
JP (3) JP6482523B2 (cg-RX-API-DMAC7.html)
KR (1) KR20150126659A (cg-RX-API-DMAC7.html)
CN (1) CN105120883B (cg-RX-API-DMAC7.html)
AR (1) AR095044A1 (cg-RX-API-DMAC7.html)
AU (1) AU2014241481B9 (cg-RX-API-DMAC7.html)
BR (1) BR112015022716A2 (cg-RX-API-DMAC7.html)
CA (1) CA2902720A1 (cg-RX-API-DMAC7.html)
CY (1) CY1119316T1 (cg-RX-API-DMAC7.html)
DK (1) DK2968446T3 (cg-RX-API-DMAC7.html)
EA (1) EA027282B1 (cg-RX-API-DMAC7.html)
ES (1) ES2633964T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20186874B (cg-RX-API-DMAC7.html)
HR (1) HRP20171188T1 (cg-RX-API-DMAC7.html)
HU (1) HUE033738T2 (cg-RX-API-DMAC7.html)
IL (1) IL240663A0 (cg-RX-API-DMAC7.html)
LT (1) LT2968446T (cg-RX-API-DMAC7.html)
MD (1) MD4599C1 (cg-RX-API-DMAC7.html)
ME (1) ME02854B (cg-RX-API-DMAC7.html)
MX (1) MX361984B (cg-RX-API-DMAC7.html)
PH (1) PH12015502060A1 (cg-RX-API-DMAC7.html)
PL (1) PL2968446T3 (cg-RX-API-DMAC7.html)
PT (1) PT2968446T (cg-RX-API-DMAC7.html)
RS (1) RS56141B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201507235YA (cg-RX-API-DMAC7.html)
SI (1) SI2968446T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201700369T1 (cg-RX-API-DMAC7.html)
TW (1) TWI608845B (cg-RX-API-DMAC7.html)
UA (1) UA115086C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014158952A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201506748B (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016154100A1 (en) * 2015-03-24 2016-09-29 Elevance Renewable Sciences, Inc. Polyol esters of metathesized fatty acids and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4434287A (en) * 1975-02-20 1984-02-28 Ciba-Geigy Corporation Cephalosporin derivatives
AR228726A1 (es) 1978-05-26 1983-04-15 Glaxo Group Ltd Procedimiento para la preparacion del antibiotico(6r,7r)-7-((z)-2-(2-aminotiazol-4-il)-2-(2-carboxiprop-2-oxiimino)acetamido)-3-(1-piridiniometil)cef-3-em-4-carboxilato
US4626534A (en) 1984-07-23 1986-12-02 Eli Lilly And Company Pharmaceutical formulation
DE3801179A1 (de) 1988-01-18 1989-07-27 Hoechst Ag Stabilisierung von cephalosporinderivaten durch trocknung mit einem stabilisator sowie stabile zubereitungsformen mit cephalosporinderivaten
JPH0331449A (ja) 1989-06-27 1991-02-12 Yamaha Corp リードフレーム用Fe―Ni合金
EP0421297B1 (en) 1989-09-30 1993-12-01 Eisai Co., Ltd. Injectable preparations containing cephalosporin medicament and the use thereof
JPH03193735A (ja) 1989-12-22 1991-08-23 Shionogi & Co Ltd グリコペプチド系抗生物質の安定化組成物
JP4142149B2 (ja) 1997-07-10 2008-08-27 明治製菓株式会社 バンコマイシンの凍結乾燥製剤
TWI335332B (en) * 2001-10-12 2011-01-01 Theravance Inc Cross-linked vancomycin-cephalosporin antibiotics
DE602004028111D1 (de) * 2003-04-16 2010-08-26 Sandoz Ag Verfahren zur herstellung von cefepim
JP2007500222A (ja) 2003-05-23 2007-01-11 セラヴァンス インコーポレーテッド 架橋グリコペプチド−セファロスポリン抗生物質
US6878868B2 (en) 2003-06-24 2005-04-12 Mcmillan Stacy L. Portable high-hat device
WO2005005436A2 (en) 2003-07-11 2005-01-20 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
TWI342312B (en) 2003-10-22 2011-05-21 Theravance Inc Hydrochloride salts of a glycopeptide phosphonate derivative
EP1656930A1 (en) 2004-11-10 2006-05-17 Basilea Pharmaceutica AG Stabilized freeze-dried formulation for cephalosporin derivatives
US20080103121A1 (en) 2006-10-30 2008-05-01 Gole Dilip J Cephalosporin derivative formulation
FR2932177B1 (fr) 2008-06-06 2012-11-30 Inst Francais Du Petrole Procede d'hydrogenation selective sur un catalyseur contenant de l'or.
JP2010105965A (ja) 2008-10-30 2010-05-13 Taiyo Yakuhin Kogyo Kk バンコマイシン製剤
WO2011035108A1 (en) 2009-09-17 2011-03-24 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
EP2504020A4 (en) 2009-11-23 2013-05-29 Eagle Pharmaceuticals Inc Daptomycin FORMULATIONS

Also Published As

Publication number Publication date
CA2902720A1 (en) 2014-10-02
PH12015502060A1 (en) 2016-01-25
SMT201700369T1 (it) 2017-09-07
RS56141B1 (sr) 2017-10-31
TWI608845B (zh) 2017-12-21
EP2968446A1 (en) 2016-01-20
AR095044A1 (es) 2015-09-16
MD4599C1 (ro) 2019-06-30
UA115086C2 (uk) 2017-09-11
ES2633964T3 (es) 2017-09-26
CN105120883A (zh) 2015-12-02
ZA201506748B (en) 2017-08-30
ME02854B (me) 2018-04-20
HUE033738T2 (hu) 2018-01-29
CN105120883B (zh) 2017-11-17
AU2014241481B2 (en) 2018-02-01
SG11201507235YA (en) 2015-10-29
MD4599B1 (ro) 2018-11-30
AU2014241481A1 (en) 2015-10-01
SI2968446T1 (sl) 2017-08-31
JP2017082016A (ja) 2017-05-18
EA027282B1 (ru) 2017-07-31
DK2968446T3 (en) 2017-08-28
MD20150101A2 (ro) 2016-02-29
MX2015012170A (es) 2015-11-30
EA201591697A1 (ru) 2016-02-29
CY1119316T1 (el) 2018-02-14
IL240663A0 (en) 2015-10-29
PL2968446T3 (pl) 2017-11-30
JP6482523B2 (ja) 2019-03-13
LT2968446T (lt) 2017-07-25
US20140274877A1 (en) 2014-09-18
JP2016513642A (ja) 2016-05-16
WO2014158952A1 (en) 2014-10-02
AU2014241481B9 (en) 2018-02-15
BR112015022716A2 (pt) 2017-07-18
EP2968446B1 (en) 2017-05-03
HK1214524A1 (en) 2016-07-29
TW201444572A (zh) 2014-12-01
KR20150126659A (ko) 2015-11-12
GEP20186874B (en) 2018-06-25
PT2968446T (pt) 2017-07-27
JP2018177817A (ja) 2018-11-15
US9161990B2 (en) 2015-10-20
MX361984B (es) 2018-12-19

Similar Documents

Publication Publication Date Title
SMT201700363T1 (it) Inibitori di bromodominio cristallini
SI3342771T1 (sl) Heterociklični amidi kot kinazni inhibitorji
LT3057586T (lt) Bromodomeno inhibitoriai
EP2969007A4 (en) HISTONE DEMETHYLASE INHIBITORS
DK3060041T3 (da) Prostacyclinforbindelser
EP2951153A4 (en) SELECTIVE HDAC3 INHIBITORS
DK3057962T3 (da) Hydrochloridsaltform til ezh2-hæmning
AR095266A1 (es) Inhibidores de bromodominios tetraciclicos
ME03465B (me) Farmaceutska kompozicija s-ketamin hidrohlorida
HUE053047T2 (hu) MDM2 inhibitor kristályos formája
EP2982666A4 (en) HETEROCYCLIC CONNECTION
HUE045209T2 (hu) Aramchol-sók
IL246054B (en) Tropomyosin-related kinase (trk) inhibitors
EP3007689A4 (en) NON-SELECTIVE KINASE HEMMER
EP3018126A4 (en) HETEROCYCLIC CONNECTION
EP3006444A4 (en) HETEROCYCLIC AMID COMPOUND
EP2980089A4 (en) HETEROCYCLIC CONNECTION
EP2982670A4 (en) HETEROCYCLIC CONNECTION
HRP20190133T1 (hr) Heterociklički spoj
HUE036054T2 (hu) Heterociklikus acetamid vegyület
DK2947066T3 (da) Phenoxyalkylaminforbindelse
HRP20171188T1 (hr) Hidrokloridne soli antibiotskog spoja
HRP20180722T1 (hr) Spoj benzotiofena
ITMI20130606A1 (it) Composti naftoeterodiazolici disostituiti
TH1501003198A (th) สารประกอบเฮเทอโรไซคลิค